MediWound Ltd. (NASDAQ:MDWD) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET
Company Participants
Monique Kosse - IR
Sharon Malka - CEO
Boaz Gur-Lavie - Chief Financial Officer
Ofer Gonen - Board Member
Lior Rosenberg - Chief Medical Officer
Cyaandi R. Dove - Investigator, Advanced Wound & Ankle Center, Las Vegas
Conference Call Participants
Unidentified Analyst - Cowen and Company
Kevin DeGeeter - Oppenheimer
Arthur He - H.C. Wainwright
Operator
Good day and welcome to the MediWound First Quarter 2022 Financial Results and Presentation of the EscharEx Phase 2 Clinical Trial Results Conference Call. At this time all participants are in a listen-only mode. Following management’s prepared remarks we will hold a Q&A session. [Operator Instructions]. At this time I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.
Monique Kosse
Thank you, operator and welcome everyone. Earlier today, MediWound issued a press release announcing its first quarter 2022 financial results and provided a corporate update. We will be reviewing those results with the management team in addition to hearing from two KOLs on the results of the EscharEx U.S. Phase 2 trial which were announced in a press release issued on May 12, 2022. You may access both releases on the company’s website under the Investors tab. With us today from management are Sharon Malka, Chief Executive Officer of MediWound; Ofer Gonen, Board Member; and Boaz Gur-Lavie, Chief Financial Officer. Also joining us are Professor Lior Rosenberg, Chief Medical Officer and Dr. Cyaandi Dove from Advanced Wound and Ankle Center, Las Vegas and an investigator in the EscharEx Phase 2 study.
Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound’s expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although, the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.
The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the cautionary notes set forth in today’s press release as well as the risk factors set forth in MediWound’s Annual Report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. At this time, I would like to turn the call over to Sharon Malka, Chief Executive Officer of MediWound. Sharon?